乳腺癌（BRCA）由于复发、转移和化疗抵抗而使得死亡率较高，构成了一个重大威胁。免疫原性细胞死亡（ICD）作为一种以引发免疫信号为特征的调节细胞死亡过程，被认定为一种有效的抗肿瘤途径。然而，ICD相关lncRNA在BRCA中的全面研究及其临床价值仍然未知。我们从癌症基因组图谱（TCGA）数据库获得了BRCA患者的转录组矩阵和相应的临床信息。进行Pearson相关性分析以鉴定ICD相关的lncRNA（ICDRLs）。为了确定已鉴定的ICDRLs的预后价值，我们采用单因素Cox回归分析、LASSO算法和多因素Cox回归分析构建了一个风险模型。随后，我们使用单因素和多因素Cox回归分析以及评分卡分析来评估预后风险模型。我们还进行了体外实验，通过定量实时聚合酶链反应（qRT-PCR）来验证生物信息学的发现结果。我们建立了一个包含五个ICDRLs的预后风险签名。随后，在BRCA的预后分层中证实了这个模型的预后价值。此外，我们还探讨了风险评分与各种临床特征和化疗反应的相关性。qRT-PCR结果证实了ICDRL的异常表达，与生物信息学数据一致。我们的发现提供了ICDRL在BRCA中的关键作用证据，并为探索BRCA患者精确治疗选择提供了新的视角。

Breast cancer (BRCA) represents a significant threat with high mortality rates due to relapse, metastasis, and chemotherapy resistance. As a regulated cell death process characterized by the induction of immunogenic signals, immunogenic cell death (ICD) has been identified as an effective anti-tumorigenesis approach. However, the comprehensive study and its clinical value of ICD-related lncRNAs in BRCA is still missing.The transcriptome matrix and corresponding clinical information of BRCA patients were obtained from The Cancer Genome Atlas (TCGA) database. Pearson correlation analysis was performed to identify ICD-related lncRNAs (ICDRLs). To determine the prognostic value of the identified ICDRLs, univariate Cox regression analysis, LASSO algorithm, and multivariate Cox regression analysis were employed to construct a risk model. The prognostic risk model was subsequently evaluated using univariate and multivariate Cox regression analysis, as well as Nomogram analysis. In vitro experiments were also conducted to validate the bioinformatics findings using quantitative real-time PCR (qRT-PCR).We established a prognostic risk signature consisting of five ICDRLs. The prognostic value of this model was subsequently confirmed in guiding BRCA prognostic stratification. Furthermore, we explored the correlation of the risk score with various clinical characteristics and chemotherapy response. qRT-PCR result confirmed the abnormal expression of ICDRLs, which was consistent with the bioinformatics data.Our findings provide evidence of the critical role of ICDRLs in BRCA and offer a novel perspective for exploring precise treatment options for BRCA patients.